| Comorbidities |
| HTA | 9 (50%) |
| Diabetes mellitus | 2 (11.1%) |
| Smoker | 9 (50%) |
| Peripheral vascular disease | 3 (16.7%) |
| Characteristics of RA |
| Disease duration (years) | 5.8±5.6 (1–17) |
| Rheumatoid nodules | 8 (44.4%) |
| Radiographic erosion | 11 (61.1%) |
| Pulmonary involvement | 3 (16.7%) |
| Renal involvement | 1 (5.6%) |
| Clinical presentation |
| Cutaneus vasculitis | 12 (66.7%) |
| Multineuritis | 12 (66.7%) |
| Mesenteric vasculitis | 2 (11.1%) |
| Systemic involvement | 8 (44.4%) |
| Renal involvement | 1 (5.6%) |
| Laboratory |
| Leukocytosis (>10x109) | 9 (50%) |
| Anemia (Hb <12g/dl) | 9 (50%) |
| Thrombocytosis | 2 (11.1%) |
| ESR | 70.76±28.46 mm3 |
| C-reactive protein | 50.27±56.77 mg/dl |
| FR positive | 18 (100%) |
| ACPA positive | 5 (100%) |
| ANA positive | 4 (22.2%) |
| ANCA positive | 4 (22.2%) |
| Cryoglobulins positives | 2 (11.1%) |
| Hypocomplementemia | 4 (22.2%) |
| AR treatment previous to the RV |
| NSADs | 17 (94.4%) |
| Glucocorticoids | 16 (88.9%) |
| Metotrexate | 12 (66.7%) |
| Antimalarial | 9 (50%) |
| D-penicillamine | 4 (22.2%) |
| Leflunomide | 5 (27.8%) |
| Golt salts | 3 (16.7%) |
| Treatment of RV |
| Glucocorticoids | 16 (88.9%) |
| Cyclophosphamide | 10 (55.6%) |
| Gammaglobulin | 1 (5.6%) |
| Azathioprine | 1 (5.6%) |
| Rituximab | 1 (5.6%) |
| Evolution |
| Improvement | 10 (55.6%) |
| Worserin | 6 (33.4%) |
| Unknown | 2 (11.1%) |
| Recurrence | 5 (27.8%) |
| Death | 3 (16.7%) |